Pamela L Lyle1, Julia A Bridge2, Jean F Simpson3, Justin M Cates4, Melinda E Sanders4. 1. Department of Pathology, Bay Pines VA Health Care System, St Petersburg, FL, USA. 2. Departments of Pathology and Microbiology, Pediatrics and Orthopaedic Surgery, Nebraska Medical Center, Omaha, NE, USA. 3. Breast Pathology Consultants, Inc., Nashville, TN, USA. 4. Department of Pathology, Immunology and Microbiology, Vanderbilt University Medical Center, Nashville, TN, USA.
Abstract
AIMS: Breast sarcomas are rare, usually occurring in the setting of malignant phyllodes tumour (MPT). Heterologous differentiation commonly resembles well-differentiated or pleomorphic liposarcoma. In extramammary sites, these subtypes have different biological behaviours and distinct genetic alterations: MDM2 and CDK4 amplification in well-differentiated liposarcoma, and polyploidy with complex structural rearrangements in pleomorphic liposarcoma. The aim of this study was to investigate foci resembling well-differentiated liposarcoma in MPT for MDM2 and CDK4 amplification. METHODS AND RESULTS: We evaluated the clinicopathological characteristics of MPTs received by the Vanderbilt Breast Consultation Service containing components resembling well-differentiated or pleomorphic liposarcoma. Cases with available tissue blocks were subjected to fluorescence in-situ hybridization with MDM2 and CDK4 probes. Thirty-eight MPTs with liposarcomatous components were available for review. The mean patient age was 49.8 years (range 26-84 years). In addition to well-differentiated liposarcoma, the following components were also present: high-grade undifferentiated sarcoma (n = 9; 23.7%), pleomorphic liposarcoma (n = 4; 10.5%), non-high-grade sarcoma not otherwise specified (n = 22; 57.9%), and malignant peripheral nerve sheath tumour-like (n = 2; 5.2%). Among 10 cases tested, none showed amplification of MDM2 or CDK4. CONCLUSIONS: This study examined molecular changes in the well-differentiated liposarcomatous components of MPT. Despite histological similarity to well-differentiated liposarcoma of soft tissues, liposarcomatous differentiation in MPT lacks the molecular phenotype characteristic of extramammary well-differentiated liposarcoma.
AIMS: Breast sarcomas are rare, usually occurring in the setting of malignant phyllodes tumour (MPT). Heterologous differentiation commonly resembles well-differentiated or pleomorphic liposarcoma. In extramammary sites, these subtypes have different biological behaviours and distinct genetic alterations: MDM2 and CDK4 amplification in well-differentiated liposarcoma, and polyploidy with complex structural rearrangements in pleomorphic liposarcoma. The aim of this study was to investigate foci resembling well-differentiated liposarcoma in MPT for MDM2 and CDK4 amplification. METHODS AND RESULTS: We evaluated the clinicopathological characteristics of MPTs received by the Vanderbilt Breast Consultation Service containing components resembling well-differentiated or pleomorphic liposarcoma. Cases with available tissue blocks were subjected to fluorescence in-situ hybridization with MDM2 and CDK4 probes. Thirty-eight MPTs with liposarcomatous components were available for review. The mean patient age was 49.8 years (range 26-84 years). In addition to well-differentiated liposarcoma, the following components were also present: high-grade undifferentiated sarcoma (n = 9; 23.7%), pleomorphic liposarcoma (n = 4; 10.5%), non-high-grade sarcoma not otherwise specified (n = 22; 57.9%), and malignant peripheral nerve sheath tumour-like (n = 2; 5.2%). Among 10 cases tested, none showed amplification of MDM2 or CDK4. CONCLUSIONS: This study examined molecular changes in the well-differentiated liposarcomatous components of MPT. Despite histological similarity to well-differentiated liposarcoma of soft tissues, liposarcomatous differentiation in MPT lacks the molecular phenotype characteristic of extramammary well-differentiated liposarcoma.
Authors: Su-Yang Liu; Nancy M Joseph; Ajay Ravindranathan; Bradley A Stohr; Nancy Y Greenland; Poonam Vohra; Elizabeth Hosfield; Iwei Yeh; Eric Talevich; Courtney Onodera; Jessica A Van Ziffle; James P Grenert; Boris C Bastian; Yunn-Yi Chen; Gregor Krings Journal: Mod Pathol Date: 2016-06-03 Impact factor: 7.842
Authors: Mei Er Tu He Ta Mi Shi; Ning Wang; Qing Yao; Shuang-Shuang Dong; Xiao Feng; Jin Zhao; Hong Zou; Li-Juan Pang; Yan Qi Journal: Onco Targets Ther Date: 2021-05-06 Impact factor: 4.147
Authors: Felipe C Geyer; Kathleen A Burke; Salvatore Piscuoglio; Charlotte K Y Ng; Anastasios D Papanastasiou; Caterina Marchiò; Pier Selenica; Marcia Edelweiss; Melissa P Murray; Edi Brogi; Robert A Soslow; Brian P Rubin; Larry Norton; Jorge S Reis-Filho; Britta Weigelt Journal: Mol Oncol Date: 2017-05-16 Impact factor: 6.603
Authors: Vikas Dembla; Neeta Somaiah; Pedro Barata; Kenneth Hess; Siqing Fu; Filip Janku; Daniel D Karp; Aung Naing; Sarina Anne Piha-Paul; Vivek Subbiah; Apostolia M Tsimberidou; Kenna Shaw; Funda Meric-Bernstam; David S Hong Journal: Oncotarget Date: 2018-09-04